Patents by Inventor Gregory J. Kaczorowski

Gregory J. Kaczorowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ophthalmic compositions for treating ocular hypertension
    Patent number: 7414067
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Grant
    Filed: March 24, 2004
    Date of Patent: August 19, 2008
    Assignees: Merck & Co. Inc., Evotec OAI
    Inventors: Edward Andrew Boyd, Michael H. Fisher, Maria L. Garcia, Gregory J. Kaczorowski, Peter T. Meinke, William H. Parsons, Stephen Price, John Stibbard
  • Maxi-k channel blockers, methods of use and process for making the same
    Patent number: 7294646
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: November 13, 2007
    Assignee: Merck & Co. Inc.
    Inventors: Maria L. Garcia, Michael A. Goetz, Gregory J. Kaczorowski, Owen B. McManus, Richard L. Monaghan, William R. Strohl, Jan S. Tkacz
  • Method for treating ocular hypertension
    Patent number: 6924306
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: August 2, 2005
    Assignee: Merck & Co. Inc.
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • Ophthalmic compositions for treating ocular hypertension
    Patent number: 6914070
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: July 5, 2005
    Assignee: Merck & Co. Inc.
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • Ophthalmic compositions for treating ocular hypertension
    Patent number: 6864383
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: March 8, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Ying-Duo Gao
  • Ophthalmic compositions for treating ocular hypertension
    Publication number: 20040054213
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 18, 2004
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Ying-Duo Gao
  • Carbocyclic potassium channel inhibitors
    Patent number: 6632836
    Abstract: The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 14, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Jennifer Chee, Maria L. Garcia, Gregory J. Kaczorowski, Frank Kayser, Andrew Kotliar, Chou Juitsai Liu, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht, William A. Schmalhofer, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Method for treating ocular hypertension
    Publication number: 20030191173
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
    Type: Application
    Filed: February 10, 2003
    Publication date: October 9, 2003
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • Ophthalmic compositions for treating ocular hypertension
    Publication number: 20030153613
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Application
    Filed: February 10, 2003
    Publication date: August 14, 2003
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • Method for treating ocular hypertension
    Patent number: 6548535
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 15, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • Ophthalmic compositions for treating ocular hypertension
    Patent number: 6545036
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • High throughput screening by measurement of intracellular calcium levels
    Patent number: 6514709
    Abstract: The present invention provides assays in which intracellular chelators are used to alter the kinetics of signal generation triggered by divalent cations, particularly calcium influx into the cell. The use of an intracellular chelator in the assay can delay and prolong the signal, allowing the signal to be detected by automated instrumentation without the need for simultaneous liquid handling at the time of detection.
    Type: Grant
    Filed: March 13, 2001
    Date of Patent: February 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Stephan K. Grant, Gregory J. Kaczorowski, Richard E. Middleton
  • Method for treating ocular hypertension
    Publication number: 20010047025
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
    Type: Application
    Filed: January 17, 2001
    Publication date: November 29, 2001
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • Ophthalmic compositions for treating ocular hypertension
    Publication number: 20010044460
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Application
    Filed: January 17, 2001
    Publication date: November 22, 2001
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • DNA encoding the .beta. subunit of a mammalian maxi-K potassium channel
    Patent number: 5776734
    Abstract: This invention relates to a heteromultimer and its use in screening pharmaceutically active compounds for modulators of maxi-K channel activity. Such modulators are useful in treating asthma, pregnant human myometrium, hypertension and angina, cerebral ischemia and in conditions where stimulation of neurotransmitter release is desired such as Alzheimer's disease and stimulation of damaged nerves.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: July 7, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Gregory J. Kaczorowski, Maria L. Garcia, Reid J. Leonard, Owen B. McManus, Richard J. Swanson, Kimberly L. Folander
  • Screening array using cells expressing recombinant .alpha. and .beta. subunits of the mammalian large-conductance (maxi-K) potassium channel
    Patent number: 5637470
    Abstract: Disclosed are nucleic acids encoding the .beta. subunit of the mammalian large-conductance ("maxi-K") potassium channel, cells transformed with such nucleic acids, and .beta. subunit proteins produced by the transformed cells. Within the invention are recombinant host cells expressing .alpha..beta. heteromultimers. Such cells or preparations made from them may be used to screen for pharmacologically active modulators of maxi-K channel activity. Such modulators are potentially useful in treating asthma, pregnant human myometrium, hypertension and angina, cerebral ischemia, and conditions where stimulation of neurotransmitter release is desired, such as in Alzheimer's disease and stimulation of damaged nerves.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: June 10, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Gregory J. Kaczorowski, Maria L. Garcia, Reid J. Leonard, Owen B. McManus, Richard J. Swanson, Kimberly L. Folander
  • Biologically active compounds
    Patent number: 5399587
    Abstract: The present invention relates to novel potassium channel agonists which are useful in activating the calcium activated Maxi-K potassium channel in mammalian neuronal and smooth muscle tissue. The claimed compounds are of the general formula: ##STR1## In addition, a novel microbiological process for producing the claimed compounds is described.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: March 21, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Robert A. Giacobbe, Otto D. Hensens, Gregory J. Kaczorowski, Seok H. Lee, Owen B. McManus, Deborah L. Zink
  • Antiarrhythmic compositions and method
    Patent number: 4604394
    Abstract: Pharmaceutical compositions and methods useful in the treatment of cardiac arrhythmias are described.
    Type: Grant
    Filed: October 1, 1984
    Date of Patent: August 5, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Gregory J. Kaczorowski, Peter K. S. Siegl